Pfizer ( – was upgraded by from a “hold” rating to a “buy” rating in a research note issued to investors on Sunday, Wall Street Zen reports.
Michael Walen is an editor at The Markets Daily. He specializes in finance, trading, and investment, with a keen focus on financial markets, financial technology, and wealth management. Michael's insights and expertise have been featured in the Oxford Eagle.